OBJECTIVES: According to the recent international data, the incidence of bloodstream catheter-associated infections is 3-8% in the structure of hospital-acquired infections in the intensive care units (ICU) and the leading cause of them are Gram positive bacteria. In this study we conducted comparative analysis of clinico-economic effectiveness of daptomycin (dapto) vs. vancomycin (vanco) usage in treatment of patients with MRSA catheter-associated infection in the ICU. METHODS: "Decision Tree" pharmacoeconomic model was built based on results of international clinical studies and data of routine practice treatment of bloodstream infections in Moscow clinics. Two variants of antibacterial treatment of patients with catheter-associated infections differing on starting products (dapto or vanco) were assessed. If the fi rst line of therapy was ineffective, patients switched over to the second line therapy covering resistant strains-meropenem and fl uconazole. Direct and indirect medical costs were assessed: cost of antibiotics and additional medical treatment, antibacterial diagnostic, laboratory and cost of bed-days in ICU and therapeutic department. Costs were based on offi cial data on hospital medical service in municipal Moscow clinics and purchasing price on medical products from price list of the biggest Russian pharmaceutical distributors. Clinical recovery was considered as effi cacy with the goal to evaluate cost-effectiveness ratio (CER) of two groups (CERdapto and CERvan accordingly). RESULTS: Better clinical effi cacy in daptomycin group resulted in lowerneeds to change antibiotic in catheter-associated infection treatment in the ICU in comparison to vancomycin group. In spite of the higher price of drug, average cost of successfully treated patient by daptomycin (CERdapto) was 227,887 RUR/pt in compare with CERvan 235,032 RUR/pt. Exchange rate is 1USD = 30 RUR. CON-CLUSIONS: Good cost-effectiveness ratio in comparison to vancomycin supports use of daptomycin as the fi rst line antibacterial therapy in bloodstream catheter-associated infections.
The clinical and quality of life data were obtained from published literature and re-confi rmed based on a questionnaire survey from a clinical expert panel of 20 hepatitis B specialists. From the perspective of China's health insurance system, cost data was calculated based on the published literature about economic burden of chronic hepatitis B. a discounting rate at 3% was used to discount utilities and medical costs happened at different years. a univariate sensitivity analysis was performed to understand the key drivers and general sensitivity of the model. RESULTS: The model results showed that the utilization of 1 year peginterferon alfa-2a treatment for HBeAg-positive CHB can prolong 0.32 QALYs, compared to the 4 years entecavir treatment (16, 394 QALYs vs. 16, 074 QALYs) . The total cost per patient treated with peginterferon alfa-2a was US$22,221, and US$19,989 for patient treated with entecavir. The discounted incremental cost per QALY gained for pegainterferon alfa-2a was US$6965. CONCLU-SIONS: The results of the model suggest that 1 year pegainterferon alfa-2a improves health outcomes in a cost-effective manner compared with 4 years entecavir in the treatment of HBeAg-positive chronic hepatitis B in China. To estimate long-term cost-effectiveness of treatment of chronic hepatitis C (CHC) patients with peginterferon alfa-2a (180 mcg/week) versus peginterferon alfa-2b (1.5 mcg/kg/week) both in combination with ribavirin (800-1400 mg/day) from the Spanish National Healthcare System perspective. METHODS: A metaanalysis of head-to-head randomized trials of peginterferon alfa-2a and peginterferon alfa-2b both plus ribavirin, evaluating sustained virological response (SVR) has been recently published. It showed RR = 1.11 (95%CI 1.04-1.19) for all genotypes, RR = 1.21 (95%CI 1.03-1.42) for G-1/4, and RR = 1.11 (95%CI 1.02-1.22) for G-2/3. a Markov model with 7 health states was developed to simulate the disease progression of adult patients with CHC for a lifetime horizon. Effi cacy, in terms of SVR, was calculated from the meta-analysis, showing a better SVR rate for peginterferon alfa-2a than for peginterferon alfa-2b: the absolute differences were of 6.0%; 7.6%; and 8.7% for all genotypes, G-1/4 and G-2/3 respectively. Transition probabilities and health states utilities were obtained from published literature. Health direct costs of peginterferon + ribavirin (48 weeks for G-1/4 and 24 weeks for G-2/3) and of disease complications were collected from Spanish databases and studies ([c] 2010). The annual discount rate was 3.5% for costs and outcomes. RESULTS: Each patient gained 0.469, 0.600 and 0.685 life-years (LY) and 0.155, 0.198 and 0.227 qualityadjusted life-years (QALY) with peginterferon alfa-2a in comparison with peginterferon alfa-2b, for all genotypes, G-1/4 and G-2/3 respectively. The savings per patient treated with peginterferon alfa-2a were c705, c672 and c1900, for all genotypes, G-1/4 and G-2/3, respectively. Peginterferon alfa-2a was the dominant treatment strategy (lower costs and higher effi cacy than peginterferon alfa-2b treatment). CONCLUSIONS: Treatment of patients with chronic hepatitis C with peginterferon alfa-2a + ribavirin is a cost-effective strategy in comparison with peginterferon alfa-2b + ribavirin for all genotypes, G-1/4 and G-2/3.
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COST-EFFECTIVENESS ANALYSIS OF TREATMENT OF CHRONIC HEPATITIS C PATIENTS WITH PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B BOTH PLUS RIBAVIRIN IN SPAIN
PIN46 KIOVIG FOR PRIMARY IMMUNODEFICIENCY: REDUCED INFUSION AND DECREASED COSTS PER INFUSION
Connolly M 1 , Simoens S 2 1 Global Market Access Solutions, St Prex, Switzerland; 2 K.U. Leuven, Leuven, Belgium OBJECTIVES: Kiovig is a new, ready-to-use 10% liquid immunoglobulin preparation that is medically indicated for the treatment of primary immunodefi ciency. This study aims to conduct an economic evaluation which compares the intravenous immunoglobulin (IVIg) preparations Kiovig, Multigam, and Sandoglobulin from the Belgian societal perspective. METHODS: Given that three prospective studies have observed no difference in outcomes, a cost-minimization analysis considered the differences in costs that can arise from these immunoglobulin products. a decision-analytic model simulated immunoglobulin treatment over a one-year time horizon. Cost items included immunoglobulin costs, pharmacy administration and nursing costs, miniforfait paid for hospital infusion, costs of adverse events, and lost productivity. Cost data were identifi ed from published sources and Belgian hospital administrators. a probabilistic sensitivity analysis explored the impact of parameter uncertainty. The price year was 2009. RESULTS: Costs per infusion cycle in adult primary immunodefi ciency patients were c1.046 (95% confi dence interval: c1.006-1.093) with Kiovig; c1.102 (c1.064-1.147) with Multigam; and c1.147 (c1.108-1.193) with Sandoglobulin. The average cost savings per infusion with Kiovig as compared to Multigam and Sandoglobulin amounted to c56 and c101 per infusion. CONCLUSIONS: Treatment costs with Kiovig were shown to be lower as compared to other IVIgs in Belgium. Reduced costs per infusion were attributed to lower costs associated with treating adverse events and the opportunity cost of nursing time and time off work for working adults.
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COST-EFFECTIVENESS ANALYSIS OF PNEUMOCOCCAL VACCINES IN TAIWAN
Chang CJ 1 , Wang PC 2 , Huang YC 3 , Wu BS 4 , Wu CL 1 , Topachevskyi O 5 , Jung W 6 1 Chang Gung University, Taoyuan, Taiwan; 2 Cathay General Hospital, Taipei, Taiwan; 3 Chang Gung Memorial Hospital, Taoyuan, Taiwan; 4 National Yang-Ming University, Taipei, Taiwan; 5 GlaxoSmithKline Biologicals, Wavre, Belgium; 6 GlaxoSmithKline, Singapore, Singapore OBJECTIVES: To evaluate cost-effectiveness of pneumococcal non-typeable Haemophilus Infl uenza protein D conjugate vaccine(PHiD-CV), 7-valent pneumococcal conjugate vaccine(PCV7), and PCV13 in Taiwan. METHODS: An age-compartmental, deterministic, static cohort model simulated in a 198,733 birth cohort the disease process of invasive disease(ID, meningitis and bacteremia), community acquired pneumonia(CAP), and acute otitis media(AOM) over life-time. The model was developed by GlaxoSmithKline and adapted with local data. For base-case analysis for all vaccines, a 4-dose(3 + 1) schedule was assumed with 95% vaccine coverage. Cost and outcomes were analyzed from health care payer perspective with 3% discount rate. Herd protection on ID, limited cross protection against 6A and 19A, minimal estimation of NTHi(non-typeable Haemophilis Infl uenzae) infection rates in ID and CAP were assumed for base case. Costs for PHiD-CV, PCV7 and PCV13 were assumed parity at 3200 New Taiwan Dollar(NTD). Epidemiological and cost data were obtained from local disease burden study. Vaccine effi cacy data were obtained from published sources. One way and probabilistic sensitivity analyses were conducted. RESULTS: Compared with PCV7, PHiD-CV is expected to prevent additional cases of 1 ID, 2,291 CAP and 63,597 AOM, with 548 additional quality-adjusted lifeyears(QALY) gained with total saving of NTD 69,347,211. Compared with PCV13, PHiD-CV is expected to prevent less cases of 4 ID and 264 CAP, but expected to prevent additional 45,111 AOM cases. PHiD-CV is expected to provide additional 181 QALY gained with total saving of NTD 14,532,124 compared to PCV13. Sensitivity analyses show the results are most sensitive to the changes of AOM related parameters, but when the AOM related parameters were changed up to +/− 20%, PHiD-CV is still cost-saving to PCV7 and PCV 13. CONCLUSIONS: PHiD-CV is expected to provide more QALYs with potential saving of total health care cost 13th Euro Abstracts A439 compared with PCV7 and PCV13. At price parity, PHiD-CV is cost-saving to PCV7 and PCV13 in Taiwan.
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PHARMACO-ECONOMICS OF ANTIBIOTICS
Simoens S K.U. Leuven, Leuven, Belgium OBJECTIVES: Antibiotics have made a signifi cant contribution to improving patient health, but policy makers and health care payers are concerned about the costs of antibiotics in addition to their effectiveness. This study aims to assess the value of antibiotics by examining published incremental cost-utility ratios of antibiotics. METHODS: Evidence was derived from cost-utility analyses of antibiotics included in the Tufts-New England Center Cost-Effectiveness Analysis Registry through September 2009. For each cost-utility analysis, the following variables were examined: publication year, target population, intervention type, country of patient sample, disease classifi cation, prevention stage, funding source, study perspective, discounting, sensitivity analysis, incremental cost-utility ratio, and methodological quality. Evidence of the value of antibiotics was summarized by calculating median incremental cost-utility ratios and frequency distributions. Associations between incremental costutility ratios on the one hand and the prevention stage, study perspective and methodological quality were examined by means of the Mann-Whitney U-test for ordinal variables. RESULTS: The analysis included 85 incremental cost-utility ratios from 23 cost-utility analyses. The fi ndings showed that 38.8% of incremental cost-utility ratios related to dominant antibiotics; 45.9% referred to antibiotics that improved effectiveness, but also increased costs; and 15.3% related to dominated antibiotics. The median ratio was c748 per quality-adjusted life-year. Using threshold values of c20,000 per quality-adjusted life-year and c50,000 per quality-adjusted life-year, the probability that an antibiotic provides value for money was 64% and 67%, respectively. No statistically signifi cant association was observed between incremental cost-utility ratios and the prevention stage (p = 0.119), study perspective (p = 0.285) or methodological quality (p = 0.146). CONCLUSIONS: The current evidence base suggests that the majority of antibiotics provide value for money.
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COST-EFFECTIVENESS OF PEGINTERFERON ALPHA-2A PLUS RIBAVIRIN FOR TREATING CRONIC HEPATITIS C VIRUS INFECTION COMPARED WITH NO TREATMENT IN MEXICO
Carlos F 1 , DeHesa 2 1 R a C Salud Consultores S.A. de C.V., México City, D.F., Mexico; 2 Hospital de Especialidades Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, D.F., Mexico OBJECTIVES: Prevalence of hepatitis C virus infection is approximately 2.2-3.0% worldwide (130-170 million people). a persistent infection develops in up to 85% of these patients, leading to chronic hepatitis C (CHC), a condition associated with serious liver-related complications. We aimed to perform an economic evaluation of peginterferon alpha-2a (PEG-IFN alpha-2a) plus ribavirin (RBV). METHODS: We developed a Markov model with 40 annual cycles to project cumulative cost and quality-adjusted life-years (QALY) for two identical cohorts of patients aged 40 years. One cohort received PEG-IFN alpha-2a 180 mcg per week plus daily doses of 1200 mg of RBV during 48 weeks for genotype 1/4 or 24 weeks for genotype 2/3. The other cohort did not receive any antiviral treatment. The analysis was performed under the perspective of national public health care system. Only direct medical costs were accounted for; these included acquisition cost of antiviral drugs and medical attention for health states incorporated into the model. Costs (expressed in 2010 Euros) and QALY were discounted at an annual rate of 5%. Transition probabilities and utility scores were gathered from published literature and cost data was based on local sources and experts' opinion. RESULTS: Average discounted costs were estimated at c15,626 for PEG-IFN alpha-2a plus RBV and at c17,350 when no antiviral treatment is given to CHC patients, leading to overall savings of c1724 per patient. Without antiviral treatment, 9.9 QALY per patient are expected. There is a gain of 2.2 QALY for patients who are treated. Results are robust to variations in model parameters. PEG-IFN alpha-2a plus RBV was both more effective and less costly than no treatment in more than half of the simulations performed in a probabilistic sensitivity analysis. CONCLUSIONS: PEG-IFN alpha-2a plus RBV is a dominant strategy compared to given no antiviral treatment to CHC patients in Mexico.
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COST-EFFECTIVENESS OF PEGINTERFERON ALPHA-2A VERSUS PEGINTERFERON ALPHA-2B FOR TREATMENT OF CHRONIC HEPATTIS C INFECTION IN MEXICO
Carlos F 1 , DeHesa 2 1 R a C Salud Consultores S.A. de C.V., México City, D.F., Mexico; 2 Hospital de Especialidades Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, D.F., Mexico OBJECTIVES: Prevalence of hepatitis C virus infection is approximately 2.2-3.0% worldwide (130-170 million people). A persistent infection develops in up to 85% of these patients, leading to chronic hepatitis C (CHC), a condition associated with serious liver-related complications. Current standard of treatment includes Peginterferon (PEG-IFN) alpha plus ribavirin (RBV). We aimed to compare two different options of PEG-IFN alpha. METHODS: We developed a Markov model with 40 annual cycles to project cumulative cost and quality-adjusted life-years (QALY) for two identical cohorts of moderate CHC patients without cirrhosis aged 40 years. One cohort received PEG-IFN alpha-2a 180 mcg per week and the other received PEG-IFN alpha-2b 1.5 mcg/Kg weekly, both combined with daily doses of 1,200 mg of RBV during 48 weeks for genotype 1/4 or 24 weeks for genotype 2/3. The analysis was performed under the perspective of national public health care system. Only direct medical costs were accounted for; these included acquisition cost of antiviral drugs and medical attention for health states incorporated into the model. Costs (expressed in 2010 Euros) and QALY were discounted at an annual rate of 5%. Transition probabilities and utility scores were gathered from published literature and cost data was based on local sources and experts' opinion. RESULTS: Average discounted costs were estimated at c16,854 for PEG-IFN alpha-2a plus RBV and at c18,247 for PEG-IFN alpha-2b plus RBV, leading to overall savings of c1,393 per patient when PEG-IFN alpha-2a is used. Discounted QALY were 12.29 for PEG-IFN alpha-2a and 12.17 for PEG-IFN alpha-2b. Results are robust to variations in model parameters. CONCLUSIONS: PEG-IFN alpha-2a plus RBV is a dominant strategy compared to given PEG-IFN alpha-2b treatment to CHC patients in Mexico.
PIN51 UPDATING THE COST-EFFECTIVENESS OF ROTAVIRUS VACCINATION IN THE NETHERLANDS
Rozenbaum MH 1 , Hak E 1 , Wilschut JC 1 , Postma MJ 2 1 University of Groningen, Groningen, Groningen, The Netherlands; 2 University of Groningen, Groningen, The Netherlands OBJECTIVES: To investigated the most important factors responsible for the large differences in previously estimated cost-effectiveness ratios and to update the costeffectiveness of rotavirus vaccination in the The Netherlands applying assumptions resulting from 2 consensus meetings with national and international experts in the fi eld, from academia, clinical environments, industry and health policy. METHODS:
We constructed a decision analytic model to compare the expected net costs and health benefi ts over a period of 5 years in two hypothetical cohorts of 180,000 children (approximating the Dutch birth cohort), one being vaccinated and one unvaccinated. The base-case analysis refl ected the most likely-but also overall conservative-estimate of cost-effectiveness from the societal perspective. Robustness of the base-case result was investigated in sensitivity and scenario analyses. RESULTS: In the base-case analysis, it was estimated that approximately 59,495 RVGE cases would occur, resulting in 11,453 GP visits and 3,238 hospitalizations. With vaccination, approximately 34,000 cases of RVGE cases are averted corresponding to a total QALY gain of 167. Assuming a total cost of vaccination of c75, vaccination would result in cost-effectiveness of c30,540 per QALY gained (c152 per case averted). Results were sensitive to the number of deaths due to RVGE, inclusion of potential herd protection, inclusion of QALY decrements of care givers, further potential tender price reduction and the exact discount rate used. CONCLUSIONS: Our economic analysis indicates that a potential national immunization programme against rotavirus can be considered costeffective if applying a threshold of c50,000 per QALY for the The Netherlands.
PIN52 AN ECONOMIC EVALUATION OF RALTEGRAVIR FOR THE TREATMENT OF ANTIRETROVIRAL-NAIVE HIV-1 INFECTED PATIENTS IN HUNGARY
Erdesz D 1 , Nagy L 1 , Brandtmuller A 1 , Kiss Z 1 , Chaudhary MA 2 , Kumar RN 3 , Elbasha EH 2 1 MSD Hungary Ltd., Budapest, Hungary; 2 Merck Research Laboratories, North Wales, PA, USA; 3 Merck & Co., Inc., Whitehouse Station, NJ, USA OBJECTIVES: Raltegravir (Merck & Co., Inc.) is an inhibitor of HIV type 1 (HIV-1) integrase, and is the fi rst drug in a new class of therapy known as the integrase inhibitors. Raltegravir has already shown to be cost-effective in HIV treatment experienced patients in Hungary. The objective of the current study is to assess if the fi rst line use of raltegravir is cost-effective compared to its use in rescue therapy from the Hungarian public payer perspective. METHODS: First line use of raltegravir was evaluated versus a protease inhibitor (PI) using a Markov model. Raltegravir was also included as a 3rd line therapy within the model arm that initiates on a PI. The Markov process comprised a three stage continuous-time model representing successive HIV therapies over a patient's life-time. Patients moved between 18 health states-based on CD4 and HIV RNA levels. Patients progressed to the next stage after they either failed current therapy or discontinued for toxicity reasons. At any time, patients could develop acquired immunodefi ciency syndrome (AIDS), suffer from a coronary heart disease (CHD) event and/or experience other adverse events. Mortality was also captured in the model. RESULTS: The incremental cost-effectiveness ratio (ICER) for initiating therapy with raltegravir versus using it as a rescue therapy was 4,075 million HUF per quality adjusted life-year gained (QALY), equivalent to $16,830/QALY. The model predicted lower cumulative incidence of CHD in the raltegravir arm versus the PI arm. (15.1% versus 16.1%). The model predicted that patients initiating on raltegravir therapy have longer life expectancy than patients starting with PI treatment over a 50-year time horizon (18.74 versus 17.17 years). CONCLUSIONS: Our long term economic model suggests that it is cost-effective to use raltegravir early in HIV therapy versus in patients who have experienced multiple failures.
